High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

doi:10.1200/JCO.2013.51.8571

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jan 2014

Willemze Roelof, Suciu Stefan, Meloni Giovanna, Labar Boris, Marie Jean-Pierre, Halkes Constantijn J M, Muus Petra, Mistrik Martin, Amadori Sergio, Specchia Giorgina, Fabbiano Francesco, Nobile Francesco, Sborgia Marco, Camera Andrea, Selleslag Dominik L D, Lefrère Francois, Magro Domenico, Sica Simona, Cantore Nicola, Beksac Meral, Berneman Zwi, Thomas Xavier, Melillo Lorella, Guimaraes Jose E, Leoni Pietro, Luppi Mario, Mitra Maria E, Bron Dominique, Fillet Georges, Marijt Erik W A, Venditti Adriano, Hagemeijer Anne, Mancini Marco, Jansen Joop, Cilloni Daniela, Meert Liv, Fazi Paola, Vignetti Marco, Trisolini Silvia M, Mandelli Franco, de Witte Theo

Abstract excerpt

PURPOSE: Cytarabine plays a pivotal role in the treatment of patients with acute myeloid leukemia (AML). Most centers use 7 to 10 days of cytarabine at a daily dose of 100 to 200 mg/m(2) for remission induction. Consensus has not been reached on the benefit of higher dosages of cytarabine. PATIENTS AND METHODS: The European Organisation for Research and Treatment of Cancer (EORTC) and Gruppo Italiano Malattie...

Topics

Adolescent
Adult
Antimetabolites, Antineoplastic
Antineoplastic Combined Chemotherapy Protocols
Consolidation Chemotherapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Cytarabine

Daunorubicin

Drug Administration Schedule

Etoposide

Europe

Female

Humans

Induction Chemotherapy

Infusions, Intravenous

Leukemia, Myeloid, Acute

Male

Middle Aged

Mutation

Source

Open in PubMed

Identifiers

PMID: 24297940
DOI: 10.1200/JCO.2013.51.8571

Genes

FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 30 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.